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BevacizumabA 64 year-old Caucasian female with advanced stage, poorly-
differentiated ovarian cancer diagnosed ﬁve years earlier developed
progressive disease while receiving carboplatin and paclitaxel for re-
current disease. Treatment was changed to docetaxel 40 mg/m2 and
bevacizumab 15 mg/kg 21 days, with intravenous dexamethasone
20 mg administered as part of the pre-chemotherapy medication reg-
imen. The patient initially complained of jaw pain after three cycles of
chemotherapy, which she attributed to temporomandibular joint dis-
order. The patient continued to have problems with jaw pain and
mucositis, and after ﬁve cycles reported removal of a large piece of
oral “plaque,” with subsequent improvement of her symptoms. She
was seen by an oral maxillofacial surgeon after losing another large
piece of plaque. The differential diagnosis included osteonecrosis of
the jaw which has been reported with bevacizumab (Guarneri et al.,
2010). Oral exam revealed a small ulceration on the lingual surface
of the left mandible at a site of exostosis, and a 1×1 mm defect
with mucosal covering distal to the second molar. The severity of ep-
ithelial breakdown exceeded that seen in typical ulcers. Maxillofacial
CT and plain ﬁlms (Fig. 1) showed no evidence of metastatic disease
or osteonecrosis. The patient was diagnosed with mucosal ulceration
associated with torus mandibularis. She had not previously been di-
agnosed with torus mandibularis but this probably was a pre-existing
condition. The symptoms resolved with oral hygiene, including a
magic mouthwash solution containing nystatin 100,000 units/ml, hy-
drocortisone 60 mg and diphenhydramine HCL, and no further dental⁎ Corresponding author at: DUMC 3079, Gynecologic Oncology, Duke University
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held for one week providing a 4-week respite from therapy. She sub-
sequently received three additional cycles of bevacizumab and doce-
taxel for a total of nine cycles, followed by two additional cycles of
single-agent bevacizumab. She ultimately developed progressive dis-
ease, and chemotherapy was changed to her current regimen of lipo-
somal doxorubicin.Review of the literature
To our knowledge, this is the ﬁrst report in the literature of muco-
sal ulceration over torus mandibularis in an ovarian cancer patient
treated with bevacizumab. Torus mandibularis is a hyperplastic
bone which presents as a bony mass on the lingual side of the mandi-
ble. Torus mandibularis and the related conditions torus palatines and
buccal and palatal exostoses are thought to be multifactorial in etiol-
ogy. The incidence of tori varies widely in the literature, from 1.4 to
69.7%, due to differences in study population ethnicities. In a study
of 448 females in the metropolitan area of Washington, D.C. the prev-
alence of torus mandibularis was 38.7%, and slightly more common
in Caucasians compared to African Americans, Hispanics, Asians or
Native Americans (Chohayeb and Volpe, 2001). This study showed no
association with age, but other studies have shown that tori occur
more commonly in young and middle-aged adults (Jainkittivong and
Langlais, 2000). Torus palatinus is more common in women, while
torus mandibularis is more common in males (Jainkittivong and
Langlais, 2000; Lo et al., 2011). The presence of tori may be positively
correlated with bone mineral density (Lo et al., 2011). The most direct
cause of tori formation is masticatory stress and bruxism (Jainkittivong
and Langlais, 2000).
There are no reports regarding bevacizumab-associated dental
ulceration over torus mandibularis. Bevacizumab is a humanized
monoclonal antibody that binds to and inhibits VEGF. VEGF inhibition
may cause avascularization and compromise of the mucosa or osteon,
allowing greater trauma from everyday activities such as chewing
and toothbrushing, and decreased ability to repair itself. Since tori
protrude from the alveolar bone it's more exposed to mechanical
abrasive situation where “weakened”mucosa would break down eas-
ily compared to healthy gingival tissue. Inhibition of VEGF, which
plays a role in the upregulation of osteoclasts, could compromise
the bone remodeling required to repair even minor trauma, and re-
sult in localized bone necrosis and periosteal death. Therefore, it is
Fig. 1. A) Arrow shows radiograph of bone level two years prior to reported tissue loss;
B) Arrow shows bone level at the time of presentation, indicating signiﬁcant bone loss.
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may have progressed to osteonecrosis of the jaw.
While our patient was not taking bisphosphonates many women
do receive this therapy. Thus it is important to note that in a review
of 923 women taking bisphosphonates, 28% were found to have oral
tori, exostoses, or both (Lo et al., 2011). In contrast to population-
based studies showing a higher prevalence of tori palatinus in fe-
males, this study showed a slightly higher incidence of lingual man-
dibular tori (15.8% vs. 13.9%). Of the 128 patients with a diagnosis
of tori palatinus, two (1.6%) eventually developed bisphosphonate-related osteonecrosis of the jaw. The association between bispho-
sphonates and oral tori/exostoses is unclear. However, the bony pro-
trusions cause the overlying tissue to become stretched and atrophic,
predisposing the area to trauma. Inhibition of osteoclasts by bispho-
sphonates may interfere with the bone remodeling necessary for
wound-healing, and increase susceptibility to osteomyelitis and
bone necrosis (Guarneri et al., 2010).
Although a cause-and-effect relationship cannot be established, it
is important to recognize that these bony protuberances are areas
which can be easily traumatized, and that bevacizumab or other anti-
angiogenic agents may predispose patients to dental ulcerations
which if unrecognized may degenerate to osteonecrosis of the jaw.
In conclusion, this case report illustrates the potential for mucosal
ulceration over a benign torus mandibularis in the setting of
bevacizumab treatment and emphasizes the need for close monitor-
ing of dental symptoms.
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